Comparison of Oral Versus Intravenous Iron Therapy in Improving Hemoglobin Status in Patients of Chronic Kidney Disease
Oral Versus Intravenous Iron Therapy for Improving Hemoglobin
DOI:
https://doi.org/10.54393/pjhs.v5i04.1377Keywords:
Chronic Kidney Disease, Hemoglobin, Intravenous Iron Supplements, Oral Iron SupplementsAbstract
Anemia (particularly iron deficiency) is an important concern in patients with chronic kidney disease (CKD) as it reflects the outcome of the disease. Objective: To compare the treatment efficacy of oral versus intravenous iron supplementation in improving the hemoglobin status of patients with chronic kidney disease not on hemodialysis or erythropoietin. Methods: Randomized controlled trial was carried out in Medicine Department of Pak Emirates Military Hospital, Rawalpindi from Jun 2023 to Dec 2023. Patients in Group I received intravenous iron sucrose 200 mg once a week diluted in 500 ml of 0.9% normal saline given over 60-90 minutes. Patients in Group O received oral iron supplementation in a dose of 325 mg (containing 65 mg of elemental iron) thrice a day taken one hour before taking their meals with a glass of water. The treatment was continued for 4 weeks. Results: Mean values of serum iron were 84.41±5.56 mcg/dl in Group I versus 84.67±5.43 mcg/dl in Group O before the start of therapy (p=0.726). Serum values for iron post-therapy were 143.40±6.01 mcg/dl in Group I versus 125.35±6.68 mcg/dl in Group O (p<0.001). Mean values for serum hemoglobin were 7.74±0.74 g/dl in Group I versus 7.61±0.82 g/dl in Group O before the start of therapy (p=0.256). Serum values of Hb post-therapy were 12.31±0.71 g/dl in Group I versus 9.91±0.82 g/dl in Group O (p<0.001). Conclusions: We conclude that Intravenous (IV) iron is superior to oral iron supplementation in improving iron stores and Hb levels in CKD patients not on dialysis and/or erythropoietin
References
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney International Supplements. 2022 Apr; 12(1): 7-11. doi: 10.1016/j.kisu.2021.11.003. DOI: https://doi.org/10.1016/j.kisu.2021.11.003
Duan J, Wang C, Liu D, Qiao Y, Pan S, Jiang D et al. Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in Chinese rural residents: a cross-sectional survey. Scientific Reports. 2019 Jul; 9(1): 10408. doi: 10.1038/s41598-019-46857-7. DOI: https://doi.org/10.1038/s41598-019-46857-7
Imtiaz and Alam A. Epidemiology and demography of Chronic Kidney Disease in Pakistan-A review of Pakistani literature. Pakistan Journal of Kidney Diseases. 2023 Mar; 7(1): 2-7. doi: 10.53778/pjkd71209. DOI: https://doi.org/10.53778/pjkd71209
Portolés J, Martín L, Broseta JJ, Cases A. Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Frontiers in Medicine. 2021 Mar; 8: 642296. doi: 10.3389/fmed.2021.642296. DOI: https://doi.org/10.3389/fmed.2021.642296
Kong JY and Hwang HS. Options for intravenous iron supplementation in hemodialysis patients. Kidney Research and Clinical Practice. 2020 Sep; 39(3): 239. doi: 10.23876/j.krcp.20.140. DOI: https://doi.org/10.23876/j.krcp.20.140
Auerbach M and Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology 2010, the American Society of Hematology Education Program Book. 2010 Dec; 2010(1): 338-47. doi: 10.1182/asheducation-2010.1.338. DOI: https://doi.org/10.1182/asheducation-2010.1.338
Vikrant S and Parashar A. The safety and efficacy of high dose ferric carboxymaltose in patients with chronic kidney disease: A single center study. Indian Journal of Nephrology. 2015 Jul; 25(4): 213-21. doi: 10.4103/0971-4065.144421. DOI: https://doi.org/10.4103/0971-4065.144421
Agrawal S, Sonawane S, Kumar S, Acharya S, Gaidhane SA, Wanjari A et al. Efficacy of oral versus injectable iron in patients with chronic kidney disease: a two-year cross-sectional study conducted at a rural teaching hospital. The Cureus Journal of Medical Sciences. 2022 Jul; 14(7). doi: 10.7759/cureus.27529. DOI: https://doi.org/10.7759/cureus.27529
Rehman IU and Khan TM. Epidemiology of chronic kidney diseases (CKD) in Malaysia and Pakistan, pathophysiology of CKD-associated pruritus and other CKD-associated dermatological disorders. Progress in Microbes & Molecular Biology. 2020 Apr; 3(1) doi: 10.36877/pmmb.a0000063. DOI: https://doi.org/10.36877/pmmb.a0000063
UpToDate. Epidemiology of chronic kidney disease. 2023. [Last cited: 26th Oct 2023]. Available at https://medilib.ir/uptodate/show/7236.
Matsushita K, Ballew SH, Wang AY, Kalyesubula R, Schaeffner E, Agarwal R. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nature Reviews Nephrology. 2022 Nov; 18(11): 696-707. doi: 10.1038/s41581-022-00616-6. DOI: https://doi.org/10.1038/s41581-022-00616-6
Hanna RM, Streja E, Kalantar-Zadeh K. Burden of anemia in chronic kidney disease: Beyond Erythropoietin. Advances in Therapy. 2021 Jan; 38(1): 52-75. doi: 10.1007/s12325-020-01524-6. DOI: https://doi.org/10.1007/s12325-020-01524-6
Gutiérrez OM. Treatment of iron deficiency anemia in CKD and end-stage kidney disease. Kidney International Reports. 2021 Sep; 6(9): 2261-9. doi: 10.1016/j.ekir.2021.05.020. DOI: https://doi.org/10.1016/j.ekir.2021.05.020
Bazeley JW and Wish JB. Recent and emerging therapies for iron deficiency in anemia of CKD: a review. American Journal of Kidney Diseases. 2022 Jun; 79(6): 868-76. doi: 10.1053/j.ajkd.2021.09.017. DOI: https://doi.org/10.1053/j.ajkd.2021.09.017
Das SN, Devi A, Mohanta BB, Choudhury A, Swain A, Thatoi PK. Oral versus intravenous iron therapy in iron deficiency anemia: an observational study. Journal of Family Medicine and Primary Care. 2020 Jul; 9(7): 3619-22. doi: 10.4103/jfmpc.jfmpc_559_20. DOI: https://doi.org/10.4103/jfmpc.jfmpc_559_20
Riccio E, Sabbatini M, Capuano I, Pellegrino AM, Petruzzelli LA, Pisani A. Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost-minimization analysis. BMC Nephrology. 2020 Dec; 21: 1-8. doi: 10.1186/s12882-020-01716-w. DOI: https://doi.org/10.1186/s12882-020-01716-w
Lopes MB, Tu C, Zee J, Guedes M, Pisoni RL, Robinson BM et al. A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps. Scientific Reports. 2021 Jan; 11(1): 1784. doi: 10.1038/s41598-020-79254-6. DOI: https://doi.org/10.1038/s41598-020-79254-6
Ganz T, Aronoff GR, Gaillard CA, Goodnough LT, Macdougall IC, Mayer G et al. Iron administration, infection, and anemia management in CKD: untangling the effects of intravenous iron therapy on immunity and infection risk. Kidney Medicine. 2020 May; 2(3): 341-53. doi: 10.1016/j.xkme.2020.01.006. DOI: https://doi.org/10.1016/j.xkme.2020.01.006
Emma LO, Hodson EM, Nistor I, Bolignano D, Webster AC, Craig JC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database of Systematic Reviews. 2019(2). doi: 10.1002/14651858.CD007857.pub3. DOI: https://doi.org/10.1002/14651858.CD007857.pub3
Elstrott B, Khan L, Olson S, Raghunathan V, DeLoughery T, Shatzel JJ. The role of iron repletion in adult iron deficiency anemia and other diseases. European Journal of Haematology. 2020 Mar; 104(3): 153-61. doi: 10.1111/ejh.13345. DOI: https://doi.org/10.1111/ejh.13345
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
